PortalPublikationenImpact of post-transplant cyclophosphamide (PTCy)-based prop...

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Standard

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. / Salas, María Queralt; Eikema, Diderik-Jan; Koster, Linda; Maertens, Johan; Passweg, Jakob; Finke, Jürgen; Broers, Annoek E C; Koc, Yener; Kröger, Nicolaus; Ozkurt, Zubeyde Nur; Pascual-Cascon, María Jesús; Platzbecker, Uwe; Van Gorkom, Gwendolyn; Schroeder, Thomas; López-Lorenzo, José Luis; Martino, Massimo; Chiusolo, Patrizia; Kaufmann, Martin; Onida, Francesco; Gurnari, Carmelo; Scheid, Christof; Drozd-Sokolowska, Joanna; Raj, Kavita; Robin, Marie; McLornan, Donal P.

in: BONE MARROW TRANSPL, Jahrgang 59, Nr. 4, 04.2024, S. 479-488.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Salas, MQ, Eikema, D-J, Koster, L, Maertens, J, Passweg, J, Finke, J, Broers, AEC, Koc, Y, Kröger, N, Ozkurt, ZN, Pascual-Cascon, MJ, Platzbecker, U, Van Gorkom, G, Schroeder, T, López-Lorenzo, JL, Martino, M, Chiusolo, P, Kaufmann, M, Onida, F, Gurnari, C, Scheid, C, Drozd-Sokolowska, J, Raj, K, Robin, M & McLornan, DP 2024, 'Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT', BONE MARROW TRANSPL, Jg. 59, Nr. 4, S. 479-488. https://doi.org/10.1038/s41409-023-02159-1

APA

Salas, M. Q., Eikema, D-J., Koster, L., Maertens, J., Passweg, J., Finke, J., Broers, A. E. C., Koc, Y., Kröger, N., Ozkurt, Z. N., Pascual-Cascon, M. J., Platzbecker, U., Van Gorkom, G., Schroeder, T., López-Lorenzo, J. L., Martino, M., Chiusolo, P., Kaufmann, M., Onida, F., ... McLornan, D. P. (2024). Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL, 59(4), 479-488. https://doi.org/10.1038/s41409-023-02159-1

Vancouver

Salas MQ, Eikema D-J, Koster L, Maertens J, Passweg J, Finke J et al. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL. 2024 Apr;59(4):479-488. https://doi.org/10.1038/s41409-023-02159-1

Bibtex

@article{a202e4b8f3154a66b0d69620bb805ef6,
title = "Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT",
abstract = "We retrospectively compared outcomes of 404 MDS patients undergoing 1st matched sibling donor allo-HCT receiving either PTCy-based (n = 66) or other {"}conventional prophylaxis{"} (n = 338; mostly calcineurin inhibitor + methotrexate or MMF). Baseline characteristics were balanced, except for higher use of myeloablative regimens in the PTCy group (52.3% vs. 38.2%, p = 0.047). Incidences of neutrophil (Day +28: 89% vs. 97%, p = 0.011) and platelet (Day +100: 89% vs. 97%, p < 0.001) engraftment were lower for PTCy-based. Day +100 cumulative incidences of grade II-IV and III-IV aGVHD, and 5-year CI of extensive cGVHD were 32%, 18% and 18% for PTCy-based and 25% (p = 0.3), 13% (p = 0.4) and 31% (p = 0.09) for the conventional cohort. Five-year OS (51% vs. 52%, p = 0.6) and GRFS (33% vs. 25%, p = 0.6) were similar between groups. Patients receiving PTCy had a trend to a lower cumulative incidence of relapse (20% vs. 33%, p = 0.06), not confirmed on multivariable analysis (p = 0.3). Although higher NRM rates were observed in patients receiving PTCy (32% vs. 21%, p = 0.02) on univariate analysis, this was not confirmed on multivariate analysis (HR 1.46, p = 0.18), and there was no resultant effect on OS (HR 1.20, p = 0.5). Based on these data, PTCy prophylaxis appears to be an attractive option for patients with MDS undergoing MSD allo-HCT.",
author = "Salas, {Mar{\'i}a Queralt} and Diderik-Jan Eikema and Linda Koster and Johan Maertens and Jakob Passweg and J{\"u}rgen Finke and Broers, {Annoek E C} and Yener Koc and Nicolaus Kr{\"o}ger and Ozkurt, {Zubeyde Nur} and Pascual-Cascon, {Mar{\'i}a Jes{\'u}s} and Uwe Platzbecker and {Van Gorkom}, Gwendolyn and Thomas Schroeder and L{\'o}pez-Lorenzo, {Jos{\'e} Luis} and Massimo Martino and Patrizia Chiusolo and Martin Kaufmann and Francesco Onida and Carmelo Gurnari and Christof Scheid and Joanna Drozd-Sokolowska and Kavita Raj and Marie Robin and McLornan, {Donal P}",
note = "{\textcopyright} 2024. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2024",
month = apr,
doi = "10.1038/s41409-023-02159-1",
language = "English",
volume = "59",
pages = "479--488",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

AU - Salas, María Queralt

AU - Eikema, Diderik-Jan

AU - Koster, Linda

AU - Maertens, Johan

AU - Passweg, Jakob

AU - Finke, Jürgen

AU - Broers, Annoek E C

AU - Koc, Yener

AU - Kröger, Nicolaus

AU - Ozkurt, Zubeyde Nur

AU - Pascual-Cascon, María Jesús

AU - Platzbecker, Uwe

AU - Van Gorkom, Gwendolyn

AU - Schroeder, Thomas

AU - López-Lorenzo, José Luis

AU - Martino, Massimo

AU - Chiusolo, Patrizia

AU - Kaufmann, Martin

AU - Onida, Francesco

AU - Gurnari, Carmelo

AU - Scheid, Christof

AU - Drozd-Sokolowska, Joanna

AU - Raj, Kavita

AU - Robin, Marie

AU - McLornan, Donal P

N1 - © 2024. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2024/4

Y1 - 2024/4

N2 - We retrospectively compared outcomes of 404 MDS patients undergoing 1st matched sibling donor allo-HCT receiving either PTCy-based (n = 66) or other "conventional prophylaxis" (n = 338; mostly calcineurin inhibitor + methotrexate or MMF). Baseline characteristics were balanced, except for higher use of myeloablative regimens in the PTCy group (52.3% vs. 38.2%, p = 0.047). Incidences of neutrophil (Day +28: 89% vs. 97%, p = 0.011) and platelet (Day +100: 89% vs. 97%, p < 0.001) engraftment were lower for PTCy-based. Day +100 cumulative incidences of grade II-IV and III-IV aGVHD, and 5-year CI of extensive cGVHD were 32%, 18% and 18% for PTCy-based and 25% (p = 0.3), 13% (p = 0.4) and 31% (p = 0.09) for the conventional cohort. Five-year OS (51% vs. 52%, p = 0.6) and GRFS (33% vs. 25%, p = 0.6) were similar between groups. Patients receiving PTCy had a trend to a lower cumulative incidence of relapse (20% vs. 33%, p = 0.06), not confirmed on multivariable analysis (p = 0.3). Although higher NRM rates were observed in patients receiving PTCy (32% vs. 21%, p = 0.02) on univariate analysis, this was not confirmed on multivariate analysis (HR 1.46, p = 0.18), and there was no resultant effect on OS (HR 1.20, p = 0.5). Based on these data, PTCy prophylaxis appears to be an attractive option for patients with MDS undergoing MSD allo-HCT.

AB - We retrospectively compared outcomes of 404 MDS patients undergoing 1st matched sibling donor allo-HCT receiving either PTCy-based (n = 66) or other "conventional prophylaxis" (n = 338; mostly calcineurin inhibitor + methotrexate or MMF). Baseline characteristics were balanced, except for higher use of myeloablative regimens in the PTCy group (52.3% vs. 38.2%, p = 0.047). Incidences of neutrophil (Day +28: 89% vs. 97%, p = 0.011) and platelet (Day +100: 89% vs. 97%, p < 0.001) engraftment were lower for PTCy-based. Day +100 cumulative incidences of grade II-IV and III-IV aGVHD, and 5-year CI of extensive cGVHD were 32%, 18% and 18% for PTCy-based and 25% (p = 0.3), 13% (p = 0.4) and 31% (p = 0.09) for the conventional cohort. Five-year OS (51% vs. 52%, p = 0.6) and GRFS (33% vs. 25%, p = 0.6) were similar between groups. Patients receiving PTCy had a trend to a lower cumulative incidence of relapse (20% vs. 33%, p = 0.06), not confirmed on multivariable analysis (p = 0.3). Although higher NRM rates were observed in patients receiving PTCy (32% vs. 21%, p = 0.02) on univariate analysis, this was not confirmed on multivariate analysis (HR 1.46, p = 0.18), and there was no resultant effect on OS (HR 1.20, p = 0.5). Based on these data, PTCy prophylaxis appears to be an attractive option for patients with MDS undergoing MSD allo-HCT.

U2 - 10.1038/s41409-023-02159-1

DO - 10.1038/s41409-023-02159-1

M3 - SCORING: Journal article

C2 - 38253869

VL - 59

SP - 479

EP - 488

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 4

ER -